Baxter to pay $4bn for dialysis firm


US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion (£2.5 billion)

‘Baxter has a legacy of innovation in dialysis, including the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home,’ said Baxter chief executive Robert Parkinson. ‘This acquisition further strengthens our global dialysis offerings by extending our portfolio in the haemodialysis segment.’

Gambro, which is based in Lund, makes products for haemodialysis and continuous renal replacement therapy, generating annual sales of $1.6 billion in 2011.

According to Baxter, more than two million people are undergoing to some form of ongoing dialysis treatment, with dialysis treatment rates increasing more than 5% annually, in part as a result of rising rates of diabetes and hypertension. The company says that healthcare providers are seeking comprehensive dialysis treatment options that vary by region, in order to serve patients based on clinical need, existing infrastructure and reimbursement policy.


Related Content

Baxter aims to divide and conquer

28 March 2014 Business

news image

Firm will split off its biopharmaceuticals business from medical products

Zeolite–polymer composite adsorbs uremic toxins

19 February 2014 Research

news image

Nanofibre mesh that soaks up creatinine is an important step towards a portable blood purification system

Most Read

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

Most Commented

UCLA spent $4.5 million on legal costs in Sangji case

20 October 2014 News and Analysis

news image

University defends spending in case brought against chemistry professor, highlighting $20 million investment in lab safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines